Anke Kleine-Tebbe

849 total citations
23 papers, 569 citations indexed

About

Anke Kleine-Tebbe is a scholar working on Oncology, Cancer Research and Dermatology. According to data from OpenAlex, Anke Kleine-Tebbe has authored 23 papers receiving a total of 569 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Cancer Research and 6 papers in Dermatology. Recurrent topics in Anke Kleine-Tebbe's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Anke Kleine-Tebbe is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Anke Kleine-Tebbe collaborates with scholars based in Germany, Switzerland and United Kingdom. Anke Kleine-Tebbe's co-authors include Carsten Denkert, Gerhard Schäller, Ilka Fuchs, Jan Budczies, Manfred Dietel, W. Lichtenegger, Christiane Richter-Ehrenstein, Julian L. Griffin, Oliver Fiehn and Dinesh Kumar Barupal and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Anke Kleine-Tebbe

23 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anke Kleine-Tebbe Germany 13 266 206 190 97 76 23 569
Wen-Yih Liang Taiwan 14 501 1.9× 146 0.7× 126 0.7× 132 1.4× 43 0.6× 22 755
C. Hudis United States 13 632 2.4× 214 1.0× 204 1.1× 100 1.0× 186 2.4× 59 801
Santai Song China 14 340 1.3× 227 1.1× 150 0.8× 157 1.6× 33 0.4× 65 608
In Ae Park South Korea 12 319 1.2× 186 0.9× 241 1.3× 88 0.9× 88 1.2× 18 605
Yoshiaki Sagara Japan 14 356 1.3× 122 0.6× 221 1.2× 120 1.2× 140 1.8× 31 639
R. Molife United Kingdom 11 291 1.1× 300 1.5× 162 0.9× 277 2.9× 32 0.4× 24 694
Virginia Picasso Italy 12 400 1.5× 314 1.5× 56 0.3× 101 1.0× 29 0.4× 16 661
Frédérique Penault‐Llorca France 11 310 1.2× 148 0.7× 79 0.4× 83 0.9× 93 1.2× 21 465
Christina Finlayson United States 13 288 1.1× 153 0.7× 303 1.6× 89 0.9× 41 0.5× 29 634
Daisaku Morita Japan 11 274 1.0× 343 1.7× 138 0.7× 310 3.2× 58 0.8× 20 809

Countries citing papers authored by Anke Kleine-Tebbe

Since Specialization
Citations

This map shows the geographic impact of Anke Kleine-Tebbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke Kleine-Tebbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke Kleine-Tebbe more than expected).

Fields of papers citing papers by Anke Kleine-Tebbe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anke Kleine-Tebbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke Kleine-Tebbe. The network helps show where Anke Kleine-Tebbe may publish in the future.

Co-authorship network of co-authors of Anke Kleine-Tebbe

This figure shows the co-authorship network connecting the top 25 collaborators of Anke Kleine-Tebbe. A scholar is included among the top collaborators of Anke Kleine-Tebbe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anke Kleine-Tebbe. Anke Kleine-Tebbe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eggemann, Holm, Cosima Brucker, Doris Augustin, et al.. (2020). Abstract P4-17-06: Treatment strategies in male breast cancer: Results of a prospective multicenter study. Cancer Research. 80(4_Supplement). P4–17. 1 indexed citations
2.
Seiler, Sabine, Sabine Schmatloch, Mattea Reinisch, et al.. (2019). Abstract P1-17-07: Cancer management and outcome of very young non-pregnant patients with breast cancer diagnosed at 40 years or younger– GBG 29. Cancer Research. 79(4_Supplement). P1–17. 1 indexed citations
3.
Harbeck, Nadia, Ulrike Nitz, Matthias Christgen, et al.. (2018). Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.. Journal of Clinical Oncology. 36(15_suppl). 572–572. 1 indexed citations
4.
Kanti, Varvara, Judith Lindner, Kathrin Hillmann, et al.. (2015). Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients. Journal of the European Academy of Dermatology and Venereology. 30(1). 112–118. 7 indexed citations
5.
Wohlrab, Johannes, Nikola Bangemann, Anke Kleine-Tebbe, et al.. (2014). Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer. Breast Cancer Targets and Therapy. 6. 115–115. 12 indexed citations
6.
Budczies, Jan, Scarlet Brockmöller, Berit Müller, et al.. (2013). Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. Journal of Proteomics. 94. 279–288. 137 indexed citations
7.
Arsenić, Ruža, Annika Lehmann, Jan Budczies, et al.. (2013). Analysis of PIK3CA Mutations in Breast Cancer Subtypes. Applied immunohistochemistry & molecular morphology. 22(1). 50–56. 44 indexed citations
8.
Wieners, Gero, Konrad Mohnike, Nils Peters, et al.. (2011). Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy – A phase II-study. Radiotherapy and Oncology. 100(2). 314–319. 39 indexed citations
9.
Blohmer, Jens‐Uwe, Peter Schmid, J. Hilfrich, et al.. (2010). Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. Annals of Oncology. 21(7). 1430–1435. 18 indexed citations
10.
Kaufmann, M., Nicolaì Maass, Serban Dan Costa, et al.. (2010). First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. European Journal of Cancer. 46(18). 3184–3191. 30 indexed citations
11.
12.
Schäller, Gerhard, Ilka Fuchs, Jan Weber, et al.. (2007). Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes. Journal of Clinical Oncology. 25(22). 3246–3250. 66 indexed citations
13.
Schaller, G. Eric, Jan Weber, Anke Kleine-Tebbe, et al.. (2005). Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 717–717. 11 indexed citations
14.
Blohmer, Jens‐Uwe, Maik Hauschild, J. Hilfrich, et al.. (2004). Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin–cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC). Journal of Clinical Oncology. 22(14_suppl). 627–627. 8 indexed citations
15.
Blohmer, Jens‐Uwe, Maik Hauschild, J. Hilfrich, et al.. (2004). Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin–cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC). Journal of Clinical Oncology. 22(14_suppl). 627–627. 2 indexed citations
16.
Fuchs, Ilka, et al.. (2003). The prognostic significance of epithelial-mesenchymal transition in breast cancer.. PubMed. 22(6A). 3415–9. 59 indexed citations
17.
Fuchs, Ilka, Uwe Kuehl, Sarah E. Coupland, et al.. (2003). Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™). Breast Cancer Research and Treatment. 82(1). 23–28. 26 indexed citations
18.
Kleine-Tebbe, Anke, et al.. (2003). Type I sensitization towards patent blue as a cause of anaphylaxis. Allergy. 58(5). 457–458. 18 indexed citations
19.
Kleine-Tebbe, Anke, et al.. (1996). [Upright birthing position--more birth canal injuries? Results of a retrospective comparative study].. PubMed. 118(8). 448–52. 2 indexed citations
20.
Kleine‐Tebbe, Jörg, et al.. (1993). Role of the Major Allergen (<i>Fel d</i> I) in Patients Sensitized to Cat Allergens. International Archives of Allergy and Immunology. 100(3). 256–262. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wen-Yih Liang Breakdown of academic impact, for papers by C. Hudis Breakdown of academic impact, for papers by Santai Song Breakdown of academic impact, for papers by In Ae Park Breakdown of academic impact, for papers by Yoshiaki Sagara Breakdown of academic impact, for papers by R. Molife Breakdown of academic impact, for papers by Virginia Picasso Breakdown of academic impact, for papers by Frédérique Penault‐Llorca Breakdown of academic impact, for papers by Christina Finlayson Breakdown of academic impact, for papers by Daisaku Morita
Rankless by CCL
2026